Back to search

Peptide record

TPDB22003

Antibacterial Anticancer Toxicity modified_plain modified
9 source-reported length (unverified)
Basic Information
TPDB22003
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A modified multi-activity (Antibacterial, Anticancer, and Toxicity) peptide record curated from Peptipedia, without an available 3D structural model. Source-reported length: 9 (unverified).
Modified, details unspecified
Sequence
KKWXKKWWK

Source notation is retained verbatim; residue notation and chemical identity have not been independently validated. The displayed length is source-reported and unverified.

Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
9 source-reported length (unverified)
Evidence Records 10 records
Evidence 1 Activity

Activity

IC50
Toxicity
287±52 µM
Cytotoxic
IC50 | 287±52 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 2 Activity

Activity

IC50
Toxicity
174±22 µM
Cytotoxic
IC50 | 174±22 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 3 Activity

Activity

IC50
Toxicity
238±69 µM
Cytotoxic
IC50 | 238±69 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 4 Activity

Activity

IC50
Toxicity
257±20 µM
Cytotoxic
IC50 | 257±20 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 5 Activity

Activity

IC50
Toxicity
40.0±1.7 µM
Cytotoxic
IC50 | 40.0±1.7 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 6 Activity

Activity

IC50
Toxicity
287
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=287 ± 52 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.
Evidence 7 Activity

Activity

IC50
Toxicity
174
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=174 ± 22 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.
Evidence 8 Activity

Activity

IC50
Toxicity
238
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=238 ± 69 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.
Evidence 9 Activity

Activity

IC50
Toxicity
257
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=257 ± 20 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.
Evidence 10 Activity

Activity

IC50
Toxicity
40.0
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=40.0 ± 1.7 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.